Last updated: February 21, 2026
What is NDC 00168-0041?
NDC 00168-0041 refers to Xeljanz (tofacitinib) tablets approved by the FDA for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is a Janus kinase (JAK) inhibitor.
Market Overview
Product Approval and Indications
- FDA approvals:
- Rheumatoid arthritis (May 2012)
- Ulcerative colitis (May 2018)
- Psoriatic arthritis (November 2017)
- Key competitors include AbbVie's Skyrizi (risankizumab), Pfizer's Xeljanz XR, and other biologics and JAK inhibitors.
Sales Trends
- Global sales reached approximately $1.2 billion in 2022.
- U.S. market consumed over 75% of sales.
- Growth driven by expanding indications and increased adoption in rheumatoid arthritis and ulcerative colitis.
Distribution Channels
- Specialty and primary care clinics
- Specialty pharmacies
- Hospital outpatient settings
Market Dynamics
Drivers
- Increasing prevalence of rheumatoid arthritis and ulcerative colitis
- Favorable reimbursement landscape for JAK inhibitors
- Growing preference for oral therapies versus injectables
Constraints
- Side effect profile risks (e.g., infections, blood clots)
- Regulatory scrutiny over safety
- Competition from biologics and emerging therapies
Regulatory Landscape
- Continued monitoring of safety concerns influences prescribing trends.
- Patent exclusivity:
- Original patent expiry expected in 2027.
- Patent litigation and biosimilar developments could influence pricing before expiration.
Price and Cost Analysis
List Price
- As of 2023, the wholesale acquisition cost (WAC) per month for 5 mg tablets is approximately $6,870 (per the Department of Veterans Affairs pricing data).
- Actual net prices are lower due to discounts, rebates, and contractual agreements.
Reimbursement Rates
- Commercial insurers typically reimburse at or just below WAC.
- Medicare Part D plans negotiate substantial rebates, reducing out-of-pocket costs for beneficiaries.
Cost Comparisons
| Parameter |
Xeljanz (NDC 00168-0041) |
Biologic Alternatives |
| Monthly Cost |
~$6,870 (list) |
$7,000–$12,000 (average biologics) |
| Route of Administration |
Oral |
Injectable infusions or injections |
| Patient Preference |
High (oral) |
Moderate (injections) |
Price Projections
Short-Term (Next 1-2 Years)
- List price expected to remain stable subject to inflation adjustments.
- Discounted prices likely to decline owing to increased negotiations and biosimilar entry.
- Entry of biosimilars may lead to price reductions between 20-40%.
Medium to Long-Term (3-5 Years)
- Competition from biosimilars and potential generics could reduce prices by 30-50%.
- Patent expirations in 2027 could accelerate pricing declines.
- The development of novel JAK inhibitors or alternative mechanisms of action may impact market share and pricing.
Factors Influencing Future Prices
- Regulatory safety updates
- Adoption rates in off-label indications
- Patent litigation outcomes
- Evolving reimbursement policies and formulary placements
Competitive Pricing Landscape
| Drug |
Manufacturer |
Indication |
Approximate Monthly Price |
Patent Status |
Key Differentiator |
| Xeljanz (NDC 00168-0041) |
Pfizer |
RA, UC, PsA |
$6,870 |
Patent until 2027 |
Oral JAK inhibitor |
| Olumiant (baricitinib) |
Eli Lilly |
RA |
~$6,000 |
Patent pending |
Competitive alternative |
| Jakafi (ruxolitinib) |
Incyte |
Myelofibrosis, Polycythemia vera |
~$7,500 |
Patent protected |
Different indication |
Key Challenges and Opportunities
- Biosimilar entry expected around 2027 may position prices downward.
- Increased off-label use in other autoimmune conditions could boost sales temporarily.
- Patent litigation may delay biosimilar market entry, maintaining higher prices longer.
Summary
NDC 00168-0041 (Xeljanz) is a leading oral JAK inhibitor in the autoimmune market. Its current list price is approximately $6,870 per month, with actual net prices lower due to rebates. Market growth is driven by expanding indications and patient preference for oral medication. Price decline pressures are anticipated post-2027 with biosimilar competition, potentially reducing costs by up to half. Strategic considerations include patent litigation outcomes, safety profile management, and formulary placements.
Key Takeaways
- Xeljanz's global sales hit around $1.2 billion in 2022, primarily in the U.S.
- List wholesale price is approximately $6,870 monthly; real prices are lower after rebates.
- Competitive landscape includes biologics and emerging biosimilars, with significant price compression expected after patent expiry.
- Market growth relies heavily on expanding indications and acceptance of oral JAK inhibitors.
- Pricing strategies will adapt closely to regulatory and safety developments.
FAQs
Q1: When is the patent for Xeljanz expiring?
A1: The original patent is expected to expire in 2027, opening the market for biosimilars.
Q2: How does the price of Xeljanz compare with biologics?
A2: Xeljanz’s list price is similar to biologic therapies but is administered orally, which is often preferred by patients, potentially influencing prescribing trends.
Q3: What factors could lower Xeljanz’s price in the near future?
A3: Biosimilar competition, patent litigation, and negotiated rebates are primary factors capable of reducing net reimbursement prices.
Q4: Are there approved biosimilars for Xeljanz?
A4: No biosimilars of Xeljanz are currently marketed; biosimilars are expected post-2027, after patent expiration.
Q5: What is the impact of safety concerns on Xeljanz pricing?
A5: Safety warnings and FDA safety communications, such as the risk of blood clots, influence prescribing patterns and reimbursement policies, indirectly affecting prices.
References
-
U.S. Food and Drug Administration. (2012). FDA approves new rheumatoid arthritis drug Xeljanz. https://www.fda.gov
-
IQVIA. (2022). The Impact of Biosimilar Entry on Market Prices. Pharmaceutical Market Data.
-
Department of Veterans Affairs. (2023). Federal Supply Schedule Pricing.
-
FDA. (2018). FDA approves Xeljanz for ulcerative colitis.
